S2k-Leitlinie: Management der Großgefäßvaskulitiden

Abisror N, Mekinian A, Lavigne C et al (2013) Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 12:1143–1149. https://doi.org/10.1016/j.autrev.2013.06.019

Abularrage CJ, Slidell MB, Sidawy AN et al (2008) Quality of life of patients with Takayasu’s arteritis. J Vasc Surg 47:131–136. https://doi.org/10.1016/j.jvs.2007.09.044 (discussion 136–137)

Achkar AA, Lie JT, Hunder GG et al (1994) How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120:987–992

Adachi O, Saiki Y, Akasaka J et al (2007) Surgical management of aortic regurgitation associated with takayasu arteritis and other forms of aortitis. Ann Thorac Surg 84:1950–1953. https://doi.org/10.1016/j.athoracsur.2007.07.025

Adizie T, Christidis D, Dharmapaliah C et al (2012) Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract 66:906–909. https://doi.org/10.1111/j.1742-1241.2012.02981.x

Adler S, Reichenbach S, Gloor A et al (2019) Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford) 58:1639–1643. https://doi.org/10.1093/rheumatology/kez091

Águeda AF, Monti S, Luqmani RA et al (2019) Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open 5:e1020. https://doi.org/10.1136/rmdopen-2019-001020

Aiello PD, Trautmann JC, McPhee TJ et al (1993) Visual prognosis in giant cell arteritis. Ophthalmology 100:550–555. https://doi.org/10.1016/s0161-6420(93)31608-8

Alba MA, García-Martínez A, Prieto-González S et al (2014) Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 93:194–201. https://doi.org/10.1097/MD.0000000000000033

Alsolaimani RS, Bhavsar SV, Khalidi NA et al (2016) Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol 43:648–656. https://doi.org/10.3899/jrheum.150143

Ando M, Kosakai Y, Okita Y et al (1999) Surgical treatment for aortic regurgitation caused by non-specific aortitis. Cardiovasc Surg 7:409–413

Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134

Armstrong AT, Tyler WB, Wood GC, Harrington TM (2008) Clinical importance of the presence of giant cells in temporal arteritis. J Clin Pathol 61:669–671. https://doi.org/10.1136/jcp.2007.049049

Aschwanden M, Daikeler T, Kesten F et al (2013) Temporal artery compression sign—A novel ultrasound finding for the diagnosis of giant cell arteritis. Ultraschall Med 34:47–50. https://doi.org/10.1055/s-0032-1312821

Aschwanden M, Imfeld S, Staub D et al (2015) The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol 33:113–115

van Assen S, Agmon-Levin N, Elkayam O et al (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70:414–422. https://doi.org/10.1136/ard.2010.137216

Bali HK, Jain S, Jain A, Sharma BK (1998) Stent supported angioplasty in Takayasu arteritis. Int J Cardiol 66(Suppl 1):S213–S217 (discussion S219–S220)

Ball EL, Walsh SR, Tang TY et al (2010) Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg 97:1765–1771. https://doi.org/10.1002/bjs.7252

Banerjee S, Grayson PC (2017) Vasculitis around the world: epidemiologic insights into causality and a need for global partnerships. J Rheumatol 44:136–139. https://doi.org/10.3899/jrheum.161468

Barra L, Yang G, Pagnoux C (2018) Non-glucocorticoid drugs for the treatment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev 17:683–693. https://doi.org/10.1016/j.autrev.2018.01.019

Berger CT, Greiff V, John S et al (2015) Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study. Clin Exp Rheumatol 33:122–125

Berger CT, Wolbers M, Meyer P et al (2009) High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) 48:258–261. https://doi.org/10.1093/rheumatology/ken480

Berlit P, Krämer M et al (2018) Zerebrale Vaskulitis und zerebrale Beteiligung bei systemischen Vaskulitiden und rheumatischen Grunderkrankungen, S1-Leitlinie in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien. Zugegriffen: 3. Juni 2019

Berthod PE, Aho-Glélé S, Ornetti P et al (2018) CT analysis of the aorta in giant-cell arteritis: a case-control study. Eur Radiol 28:3676–3684. https://doi.org/10.1007/s00330-018-5311-8

Blockmans D, de Ceuninck L, Vanderschueren S et al (2006) Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 55:131–137. https://doi.org/10.1002/art.21699

Blockmans D, Coudyzer W, Vanderschueren S et al (2008) Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 47:1179–1184. https://doi.org/10.1093/rheumatology/ken119

Blockmans D, Stroobants S, Maes A, Mortelmans L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108:246–249

ter Borg EJ, Haanen HCM, Seldenrijk CA (2007) Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup. Clin Rheumatol 26:529–532. https://doi.org/10.1007/s10067-006-0332-0

Both M, Aries PM, Müller-Hülsbeck S et al (2006) Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant-cell arteritis. Ann Rheum Dis 65:1124–1130. https://doi.org/10.1136/ard.2005.048470

Boyev LR, Miller NR, Green WR (1999) Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 128:211–215. https://doi.org/10.1016/s0002-9394(99)00101-4

de Boysson H, Boutemy J, Creveuil C et al (2013) Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 43:105–112. https://doi.org/10.1016/j.semarthrit.2012.12.023

de Boysson H, Daumas A, Vautier M et al (2018) Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev 17:391–398. https://doi.org/10.1016/j.autrev.2017.11.029

de Boysson H, Liozon E, Lambert M et al (2016) 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: a multicenter cohort of 130 patients. Medicine (Baltimore) 95:e3851. https://doi.org/10.1097/MD.0000000000003851

de Boysson H, Liozon E, Lambert M et al (2017) Giant-cell arteritis: do we treat patients with large-vessel involvement differently? Am J Med 130:992–995. https://doi.org/10.1016/j.amjmed.2017.03.054

de Boysson H, Liozon E, Larivière D et al (2017) Giant cell arteritis-related stroke: a retrospective multicenter case-control study. J Rheumatol 44:297–303. https://doi.org/10.3899/jrheum.161033

de Boysson H, Liozon E, Ly KH et al (2019) The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol 37(Suppl 117):57–60

Breuer GS, Nesher R, Reinus K, Nesher G (2013) Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. Isr Med Assoc J 15:271–274

Brito-Zerón P, Kostov B, Bosch X et al (2016) Therapeutic approach to IgG4-related disease: a systematic review. Medicine (Baltimore) 95:e4002. https://doi.org/10.1097/MD.0000000000004002

Broder MS, Sarsour K, Chang E et al (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46:246–252. https://doi.org/10.1016/j.semarthrit.2016.05.009

Buttgereit F, Brabant T et al (2018) S3 guidelines on treatment of polymyalgia rheumatica: evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol 77:429–441. https://doi.org/10.1007/s00393-018-0476-8

Calderón-Goercke M, Loricera J, Aldasoro V et al (2019) Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum 49:126–135. https://doi.org/10.1016/j.semarthrit.2019.01.003

Cavazza A, Muratore F, Boiardi L et al (2014) Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol 38:1360–1370. https://doi.org/10.1097/PAS.0000000000000244

Chan CC, Paine M, O’Day J (2001) Steroid management in giant cell arteritis. Br J Ophthalmol 85:1061–1064

Chandran A, Udayakumar PD, Kermani TA et al (2015) Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol 33:98–102

Chatelain D, Duhaut P, Schmidt J et al (2009) Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis 68:84–88. https://doi.org/10.1136/ard.2007.084947

Chauhan SK, Singh M, Nityanand S (2007) Reactivity of gamma/delta T cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. Arthritis Rheum 56:2798–2802. https://doi.org/10.1002/art.22801

Chevalet P, Barrier JH, Pottier P et al (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 27:1484–1491

Chrysidis S, Duftner C, Dejaco C et al (2018) Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD Open 4:e598. https://doi.org/10.1136/rmdopen-2017-000598

Chung JB, Armstrong K, Schwartz JS, Albert D (2000) Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43:1841–1848. https://doi.org/10.1002/1529-0131(200008)43:8〈1841::AID-ANR21〉3.0.CO;2‑Q

Comarmond C, Biard L, Lambert M et al (2017) Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation 136:1114–1122. https://doi.org/10.1161/CIRCULATIONAHA.116.027094

Comarmond C, Plaisier E, Dahan K et al (2012) Anti TNF‑α in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev 11:678–684. https://doi.org/10.1016/j.autrev.2011.11.025

Conway R, O’Neill L, Gallagher P et al (2018) Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum 48:523–528. https://doi.org/10.1016/j.semarthrit.2018.04.004

Conway R, O’Neill L, O’Flynn E et al (2016) Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 75:1578–1579. https://doi.org/10.1136/annrheumdis-2016-209351

Conway R, Smyth AE, Kavanagh RG et al (2018) Diagnostic utility of computed tomographic angiography in giant-cell arteritis. Stroke 49:2233–2236. https://doi.org/10.1161/STROKEAHA.118.021995

Crowson CS, Matteson EL, Myasoedova E et al (2011) The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 63:633–639. https://doi.org/10.1002/art.30155

Czihal M, Piller A, Schroettle A et al (2013) Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study. Rheumatology (Oxford) 52:282–286. https://doi.org/10.1093/rheumatology/kes239

Czihal M, Piller A, Schroettle A et al (2015) Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. J Vasc Surg 61:1285–1291. https://doi.org/10.1016/j.jvs.2014.12.045

Czihal M, Tatò F, Rademacher A et al (2012) Involvement of the femoropopliteal arteries in giant cell arteritis: clinical and color duplex sonography. J Rheumatol 39:314–321. https://doi.org/10.3899/jrheum.110566

Dachverband Osteologie (2017) http://www.dv-osteologie.org/uploads/Leitlinie%202017/Finale%20Version%20Leitlinie%20Osteoporose%202017_end.pdf. Zugegriffen: 3. Juni 2019

Dai D, Wang Y, Jin H et al (2017) The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Int 37:1083–1088. https://doi.org/10.1007/s00296-017-3704-7

De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45:136–138

Dejaco C, Duftner C, Buttgereit F et al (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 56:506–515. https://doi.org/10.1093/rheumatology/kew273

Dejaco C, Ramiro S, Duftner C et al (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77:636–643. https://doi.org/10.1136/annrheumdis-2017-212649

Dejaco C, Singh YP, Perel P et al (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74:1799–1807. https://doi.org/10.1136/annrheumdis-2015-207492

Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB (1988) Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 47:733–739

DGRh Website der Deutschen Gesellschaft für Rheumatologie. https://dgrh.de/Start/Versorgung/Therapie%C3%BCberwachung/Therapie%C3%BCberwachungsb%C3%B6gen.html. Zugegriffen: 11. Nov. 2019

Diamantopoulos AP, Haugeberg G, Hetland H et al (2014) Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res 66:113–119. https://doi.org/10.1002/acr.22178

Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55:66–70. https://doi.org/10.1093/rheumatology/kev289

Dong H, Che W, Jiang X et al (2017) An unrecognised presentation of Takayasu arteritis: superficial femoral artery involvement. Clin Exp Rheumatol 35(Suppl 103):83–87

Duftner C, Dejaco C, Sepriano A et al (2018) Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 4:e612. https://doi.org/10.1136/rmdopen-2017-000612

Duru N, van der Goes MC, Jacobs JWG et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913. https://doi.org/10.1136/annrheumdis-2013-203249

Ehrenstein B (2018) Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment. Z Rheumatol 77:493–507. https://doi.org/10.1007/s00393-018-0488-4

Einspieler I, Thürmel K, Pyka T et al (2015) Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging 42:1012–1024. https://doi.org/10.1007/s00259-015-3007-8

Erbel R, Aboyans V, Boileau C et al (2014) 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35:2873–2926. https://doi.org/10.1093/eurheartj/ehu281

Espitia O, Néel A, Leux C et al (2012) Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup. J Rheumatol 39:2157–2162. https://doi.org/10.3899/jrheum.120511

Espitia O, Samson M, Le Gallou T et al (2016) Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. Autoimmun Rev 15:571–576. https://doi.org/10.1016/j.autrev.2016.02.016

Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122:502–507

Ezeonyeji AN, Borg FA, Dasgupta B (2011) Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol 30:259–262. https://doi.org/10.1007/s10067-010-1616-y

Fields CE, Bower TC, Cooper LT et al (2006) Takayasu’s arteritis: operative results and influence of disease activity. J Vasc Surg 43:64–71. https://doi.org/10.1016/j.jvs.2005.10.010

de Franciscis S, Serra R, Luongo A et al (2007) The management of Takayasu’s arteritis: personal experience. Ann Vasc Surg 21:754–760. https://doi.org/10.1016/j.avsg.2007.03.021

Gagné-Loranger M, Dumont É, Voisine P et al (2016) Giant cell aortitis: clinical presentation and outcomes in 40 patients consecutively operated on. Eur J Cardiothorac Surg 50:555–559. https://doi.org/10.1093/ejcts/ezw041

García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC (2004) Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum 51:674–678. https://doi.org/10.1002/art.20541

Germanò G, Macchioni P, Possemato N et al (2017) Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: correlation with positron emission tomography findings. Arthritis Care Res 69:143–149. https://doi.org/10.1002/acr.22906

Germanò G, Muratore F, Cimino L et al (2015) Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. Rheumatology (Oxford) 54:400–404. https://doi.org/10.1093/rheumatology/keu241

Ghinoi A, Pipitone N, Nicolini A et al (2012) Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford) 51:730–734. https://doi.org/10.1093/rheumatology/ker329

Goel R, Danda D, Kumar S, Joseph G (2013) Rapid control of disease activity by tocilizumab in 10 „difficult-to-treat“ cases of Takayasu arteritis. Int J Rheum Dis 16:754–761. https://doi.org/10.1111/1756-185X.12220

Goel R, Danda D, Mathew J, Edwin N (2010) Mycophenolate mofetil in Takayasu’s arteritis. Clin Rheumatol 29:329–332. https://doi.org/10.1007/s10067-009-1333-6

González-Gay MA, Blanco R, Rodríguez-Valverde V et al (1998) Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41:1497–1504. https://doi.org/10.1002/1529-0131(199808)41:8〈1497::AID-ART22〉3.0.CO;2‑Z

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I et al (2009) Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 88:227–235. https://doi.org/10.1097/MD.0b013e3181af4518

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61:1454–1461. https://doi.org/10.1002/art.24459

Graham E, Holland A, Avery A, Russell RW (1981) Prognosis in giant-cell arteritis. Br Med J 282:269–271

Grayson PC, Alehashemi S, Bagheri AA et al (2018) 18F-Fluorodeoxyglucose-positron emission tomography as an imaging Biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol 70:439–449. https://doi.org/10.1002/art.40379

Grossman C, Barshack I, Koren-Morag N et al (2017) Risk factors for severe cranial ischaemic events in patients with giant cell arteritis. Clin Exp Rheumatol 35(Suppl 103):88–93

Gudbrandsson B, Molberg Ø, Palm Ø (2017) TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 19:99. https://doi.org/10.1186/s13075-017-1316-y

Gülcü A, Gezer NS, Akar S et al (2017) Long-term follow-up of endovascular repair in the management of arterial stenosis caused by Takayasu’s arteritis. Ann Vasc Surg 42:93–100. https://doi.org/10.1016/j.avsg.2016.10.066

Hachulla E, Boivin V, Pasturel-Michon U et al (2001) Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 19:171–176

Hatemi G, Christensen R, Bang D et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77:808–818. https://doi.org/10.1136/annrheumdis-2018-213225

Hauenstein C, Reinhard M, Geiger J et al (2012) Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Arthritis Rheumatol 51:1999–2003. https://doi.org/10.1093/rheumatology/kes153

Hayreh SS, Zimmerman B (2003) Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110:1204–1215. https://doi.org/10.1016/S0161-6420(03)00228-8

Hayreh SS, Zimmerman B, Kardon RH (2002) Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 80:355–367

Hazlewood GS, Thorne JC, Pope JE et al (2016) The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75:1003–1008. https://doi.org/10.1136/annrheumdis-2014-206504

Hellmich B, Agueda A, Monti S et al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672

Herlyn K, Buckert F, Gross WL, Reinhold-Keller E (2014) Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 53:882–889. https://doi.org/10.1093/rheumatology/ket440

Herlyn K, Gross WL, Reinhold-Keller E (2008) Longitudinal effects of structured patient education programs for vasculitis patients. Z Rheumatol 67:206–210. https://doi.org/10.1007/s00393-008-0290-9

Hernández-Rodríguez J, García-Martínez A, Casademont J et al (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47:29–35

Hernández-Rodríguez J, Murgia G, Villar I et al (2016) Description and validation of histological patterns and proposal of a dynamic model of inflammatory infiltration in giant-cell arteritis. Medicine (Baltimore) 95:e2368. https://doi.org/10.1097/MD.0000000000002368

Hernández-Rodríguez J, Tan CD, Rodríguez ER, Hoffman GS (2009) Gynecologic vasculitis: an analysis of 163 patients. Medicine (Baltimore) 88:169–181. https://doi.org/10.1097/MD.0b013e3181a577 f3

Hinojosa CA, Anaya-Ayala JE, Gomez-Arcive Z et al (2017) Factors associated with need for revascularisation in non-coronary arterial occlusive lesions secondary to Takayasu’s arteritis. Eur J Vasc Endovasc Surg 54:397–404. https://doi.org/10.1016/j.ejvs.2017.05.020

Hočevar A, Ješe R, Rotar Ž, Tomšič M (2019) Does leflunomide have a role in giant cell arteritis? An open-label study. Clin Rheumatol 38:291–296. https://doi.org/10.1007/s10067-018-4232-x

Hocevar A, Rotar Z, Jese R et al (2016) Do early diagnosis and glucocorticoid treatment decrease the risk of permanent visual loss and early relapses in giant cell arteritis: a prospective longitudinal study. Medicine (Baltimore) 95:e3210. https://doi.org/10.1097/MD.0000000000003210

Hoffman GS, Cid MC, Hellmann DB et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309–1318. https://doi.org/10.1002/art.10262

Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630

Hoffman GS, Leavitt RY, Kerr GS et al (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582

Hoffman GS, Merkel PA, Brasington RD et al (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304. https://doi.org/10.1002/art.20300

Hong S, Ghang B, Kim Y‑G et al (2017) Longterm outcomes of renal artery involvement in Takayasu arteritis. J Rheumatol 44:466–472. https://doi.org/10.3899/jrheum.160974

Huang Y, Ma X, Li M et al (2019) Carotid contrast-enhanced ultrasonographic assessment of disease activity in Takayasu arteritis. Eur Heart J Cardiovasc Imaging 20:789–795. https://doi.org/10.1093/ehjci/jey197

Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128

Hunder GG, Sheps SG, Allen GL, Joyce JW (1975) Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82:613–618

Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol 12:964–972

Jakobsson K, Jacobsson L, Mohammad AJ et al (2016) The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskelet Disord 17:363. https://doi.org/10.1186/s12891-016-1225-2

Jamilloux Y, Liozon E, Pugnet G et al (2013) Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. PLoS One 8:e68713. https://doi.org/10.1371/journal.pone.0068713

Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715

Jeong HS, Jung JH, Song GG et al (2017) Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: a meta-analysis. Medicine (Baltimore) 96:e7558. https://doi.org/10.1097/MD.0000000000007558

Jobard S, Magnant J, Blasco H et al (2017) Quality of life of patients treated for giant cell arteritis: a case-control study. Clin Rheumatol 36:2055–2062. https://doi.org/10.1007/s10067-017-3619-4

Jover JA, Hernández-García C, Morado IC et al (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106–114

Jung JH, Lee YH, Song GG et al (2018) Endovascular versus open surgical intervention in patients with Takayasu’s arteritis: a meta-analysis. Eur J Vasc Endovasc Surg 55:888–899. https://doi.org/10.1016/j.ejvs.2018.02.030

Kaiser M, Weyand CM, Björnsson J, Goronzy JJ (1998) Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 41:623–633. https://doi.org//10.1002/1529-0131(199804)41:4〈623::AID-ART9〉3.0.CO;2‑6

Karahaliou M, Vaiopoulos G, Papaspyrou S et al (2006) Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 8:R116. https://doi.org/10.1186/ar2003

Kermani TA, Schmidt J, Crowson CS et al (2012) Utility of erythrocyte sedimentation rate and C‑reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 41:866–871. https://doi.org/10.1016/j.semarthrit.2011.10.005

Kermani TA, Warrington KJ (2011) Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. Curr Opin Rheumatol 23:38–42. https://doi.org/10.1097/BOR.0b013e3283410072

Kermani TA, Warrington KJ, Crowson CS et al (2013) Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 72:1989–1994. https://doi.org/10.1136/annrheumdis-2012-202408

Kermani TA, Warrington KJ, Cuthbertson D et al (2015) Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 42:1213–1217. https://doi.org/10.3899/jrheum.141347

Kermani TA, Ytterberg SR, Warrington KJ (2011) Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res 63:761–765. https://doi.org/10.1002/acr.20435

Kim HJ, Lee C‑S, Kim JS et al (2011) Outcomes after endovascular treatment of symptomatic patients with Takayasu’s arteritis. Interv Neuroradiol 17:252–260. https://doi.org/10.1177/159101991101700219

Kim IY, Eun YH, Jeong H et al (2017) Clinical characteristics and outcomes of 61 patients with chronic periaortitis including IgG4-related and non-IgG4-related cases. Int J Rheum Dis 20:1751–1762. https://doi.org/10.1111/1756-185X.13194

Kim Y‑W, Kim D‑I, Park YJ et al (2012) Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg 55:693–700. https://doi.org/10.1016/j.jvs.2011.09.051

Klink T, Geiger J, Both M et al (2014) Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 273:844–852. https://doi.org/10.1148/radiol.14140056

Kobayashi Y, Ishii T, Harigae H (2014) Takayasu’s arteritis. In: Ball GV, Fessler BJ, Bridges SL (Hrsg) Oxf. Textb. Vasc., 3. Aufl. Oxford University Press, Oxford, S 319–329

Koster MJ, Yeruva K, Crowson CS et al (2019) Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol 46:501–508. https://doi.org/10.3899/jrheum.180429

Kwon OC, Oh JS, Park M‑C et al (2019) Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol 287:111–115. https://doi.org/10.1016/j.ijcard.2019.02.046

Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48:658–661

Labarca C, Koster MJ, Crowson CS et al (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55:347–356. https://doi.org/10.1093/rheumatology/kev348

Labarca C, Makol A, Crowson CS et al (2016) Retrospective comparison of open versus endovascular procedures for Takayasu arteritis. J Rheumatol 43:427–432. https://doi.org/10.3899/jrheum.150447

Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 69:837–845. https://doi.org/10.1002/art.40044

Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 69:846–853. https://doi.org/10.1002/art.40037

Lariviere D, Benali K, Coustet B et al (2016) Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: a real-life prospective study. Medicine (Baltimore) 95:e4146. https://doi.org/10.1097/MD.0000000000004146

Laurent C, Ricard L, Fain O et al (2019) PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. Sci Rep 9:12388. https://doi.org/10.1038/s41598-019-48709-w

Lee B‑B, Laredo J, Neville R, Villavicencio JL (2009) Endovascular management of takayasu arteritis: is it a durable option? Vascular 17:138–146. https://doi.org/10.2310/6670.2009.00012

Lee MS, Smith SD, Galor A, Hoffman GS (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54:3306–3309. https://doi.org/10.1002/art.22141

Leon L, Rodriguez-Rodriguez L, Morado I et al (2018) Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. Clin Exp Rheumatol 36(Suppl 111):121–128

Les I, Pijoán JI, Rodríguez-Álvarez R et al (2015) Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol 33:90–97

Li J, Yang Y, Zhao J et al (2016) The efficacy of mycophenolate mofetil for the treatment of Chinese Takayasu’s arteritis. Sci Rep 6:38687. https://doi.org/10.1038/srep38687

Lie JT (1990) Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 33:1074–1087. https://doi.org/10.1002/art.1780330804

Liozon E, Roblot P, Paire D et al (2000) Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford) 39:1089–1094

Loock J, Henes J, Kötter I et al (2012) Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 30:S70–S76

Loricera J, Blanco R, Hernández JL et al (2015) Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum 44:717–723. https://doi.org/10.1016/j.semarthrit.2014.12.005

Lottspeich C, Dechant C, Köhler A et al (2019) Assessment of disease activity in Takayasu arteritis: potential role of contrast-enhanced ultrasound. Ultraschall Med 40:638–645. https://doi.org/10.1055/a-0817-5423

Luo XY, Wu QH, Zhang FX (2017) Open and endovascular management of severe cerebral ischemia in Takayasu’s arteritis. Ann Vasc Surg 42:101–110. https://doi.org/10.1016/j.avsg.2017.01.001

Luqmani R, Lee E, Singh S et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20:1–238. https://doi.org/10.3310/hta20900

Ly KH, Dalmay F, Gondran G et al (2016) Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: a single-center, retrospective study of 70 patients. Medicine (Baltimore) 95:e4974. https://doi.org/10.1097/MD.0000000000004974

Mackie SL, Hensor EMA, Morgan AW, Pease CT (2014) Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis 73:143–148. https://doi.org/10.1136/annrheumdis-2012-202145

Maeda H, Handa N, Matsumoto M et al (1991) Carotid lesions detected by B‑mode ultrasonography in Takayasu’s arteritis: „macaroni sign“ as an indicator of the disease. Ultrasound Med Biol 17:695–701. https://doi.org/10.1016/0301-5629(91)90101-2

Mahr AD, Jover JA, Spiera RF et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56:2789–2797. https://doi.org/10.1002/art.22754

Makkuni D, Bharadwaj A, Wolfe K et al (2008) Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 47:488–490. https://doi.org/10.1093/rheumatology/ken012

Ma-Krupa W, Jeon M‑S, Spoerl S et al (2004) Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199:173–183. https://doi.org/10.1084/jem.20030850

Maleszewski JJ, Younge BR, Fritzlen JT et al (2017) Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol 30:788–796. https://doi.org/10.1038/modpathol.2017.10

Martinez-Lado L, Calviño-Díaz C, Piñeiro A et al (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90:186–193. https://doi.org/10.1097/MD.0b013e31821c4fad

Martínez-Taboada VM, López-Hoyos M, Narvaez J, Muñoz-Cacho P (2014) Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev 13:788–794. https://doi.org/10.1016/j.autrev.2014.02.006

Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630. https://doi.org/10.1136/ard.2007.082115

Mason JC (2018) Surgical intervention and its role in Takayasu arteritis. Best Pract Res Clin Rheumatol 32:112–124. https://doi.org/10.1016/j.berh.2018.07.008

Matsuura K, Ogino H, Kobayashi J et al (2005) Surgical treatment of aortic regurgitation due to Takayasu arteritis: long-term morbidity and mortality. Circulation 112:3707–3712. https://doi.org/10.1161/CIRCULATIONAHA.105.535724

Mazlumzadeh M, Hunder GG, Easley KA et al (2006) Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54:3310–3318. https://doi.org/10.1002/art.22163

Mekinian A, Comarmond C, Resche-Rigon M et al (2015) Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation 132:1693–1700. https://doi.org/10.1161/CIRCULATIONAHA.114.014321

Mekinian A, Néel A, Sibilia J et al (2012) Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 51:882–886. https://doi.org/10.1093/rheumatology/ker380

Mekinian A, Resche-Rigon M, Comarmond C et al (2018) Efficacy of tocilizumab in Takayasu arteritis: multicenter retrospective study of 46 patients. J Autoimmun 91:55–60. https://doi.org/10.1016/j.jaut.2018.04.002

Miller DV, Maleszewski JJ (2011) The pathology of large-vessel vasculitides. Clin Exp Rheumatol 29:S92–98

Min P‑K, Park S, Jung J‑H et al (2005) Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasu’s arteritis. J Endovasc Ther 12:28–34. https://doi.org/10.1583/12-01-04-1329.1

Mirouse A, Biard L, Comarmond C et al (2019) Overall survival and mortality risk factors in Takayasu’s arteritis: a multicenter study of 318 patients. J Autoimmun 96:35–39. https://doi.org/10.1016/j.jaut.2018.08.001

Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of Takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60–68. https://doi.org/10.1111/1756-185X.13285

Mollan SP, Sharrack N, Burdon MA, Denniston AK (2014) Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010453.pub2

Molloy ES, Langford CA, Clark TM et al (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567–1569. https://doi.org/10.1136/ard.2008.093260

Monti S, Águeda AF, Luqmani RA et al (2019) Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5:e1003. https://doi.org/10.1136/rmdopen-2019-001003

Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323. https://doi.org/10.1136/ard.2008.088351

Muratore F, Boiardi L, Cavazza A et al (2016) Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis. J Autoimmun 69:94–101. https://doi.org/10.1016/j.jaut.2016.03.005

Muratore F, Cavazza A, Boiardi L et al (2016) Histopathologic findings of patients with biopsy-negative giant cell arteritis compared to those without arteritis: a population-based study. Arthritis Care Res 68:865–870. https://doi.org/10.1002/acr.22736

Muratore F, Kermani TA, Crowson CS et al (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 54:463–470. https://doi.org/10.1093/rheumatology/keu329

Nakaoka Y, Higuchi K, Arita Y et al (2013) Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J 54:405–411

Nakaoka Y, Isobe M, Takei S et al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TA)KT study). Ann Rheum Dis 77:348–354. https://doi.org/10.1136/annrheumdis-2017-211878

Narváez J, Bernad B, Gómez-Vaquero C et al (2008) Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 26:S57–S62

Narváez J, Bernad B, Nolla JM, Valverde J (2007) Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 36:322–327. https://doi.org/10.1016/j.semarthrit.2006.10.001

Narváez J, Bernad B, Roig-Vilaseca D et al (2007) Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 37:13–19. https://doi.org/10.1016/j.semarthrit.2006.12.005

Nesher G, Berkun Y, Mates M et al (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50:1332–1337. https://doi.org/10.1002/art.20171

Nesher G, Nesher R, Mates M et al (2008) Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 26:S30–S34

Niederkohr RD, Levin LA (2007) A Bayesian analysis of the true sensitivity of a temporal artery biopsy. Invest Ophthalmol Vis Sci 48:675–680. https://doi.org/10.1167/iovs.06-1106

Nielsen BD, Gormsen LC, Hansen IT et al (2018) Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging 45:1119–1128. https://doi.org/10.1007/s00259-018-4021-4

Nielsen BD, Hansen IT, Kramer S et al (2019) Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study. Eur J Nucl Med Mol Imaging 46:184–193. https://doi.org/10.1007/s00259-018-4106-0

Novikov PI, Smitienko IO, Moiseev SV (2013) Tumor necrosis factor alpha inhibitors in patients with Takayasu’s arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clin Rheumatol 32:1827–1832. https://doi.org/10.1007/s10067-013-2380-6

Novikov PI, Smitienko IO, Sokolova MV et al (2018) Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology (Oxford) 57:2101–2105. https://doi.org/10.1093/rheumatology/key197

Nunes G, Neves FS, Melo FM et al (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 50:291–298

Ohigashi H, Haraguchi G, Konishi M et al (2012) Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 76:1004–1011

Ohigashi H, Tamura N, Ebana Y et al (2017) Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 69:774–778. https://doi.org/10.1016/j.jjcc.2016.07.009

Omma A, Erer B, Karadag O et al (2017) Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clin Exp Rheumatol 35(Suppl 103):77–82

Onen F, Akkoc N (2017) Epidemiology of Takayasu arteritis. Presse Med 46:e197–e203. https://doi.org/10.1016/j.lpm.2017.05.034

Park HS, Do YS, Park KB et al (2013) Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis: angioplasty versus stent placement. Eur J Radiol 82:1913–1918. https://doi.org/10.1016/j.ejrad.2013.06.019

Park JW, Curtis JR, Moon J et al (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77:644–649. https://doi.org/10.1136/annrheumdis-2017-211796

Patil P, Williams M, Maw WW et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33:103–106

Pazzola G, Muratore F, Pipitone N et al (2017) Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kex249

Prieto-González S, Arguis P, García-Martínez A et al (2012) Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 71:1170–1176. https://doi.org/10.1136/annrheumdis-2011-200865

Proven A, Gabriel SE, Orces C et al (2003) Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49:703–708. https://doi.org/10.1002/art.11388

Pugnet G, Sailler L, Bourrel R et al (2015) Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study. J Rheumatol 42:316–322. https://doi.org/10.3899/jrheum.140906

Pugnet G, Sailler L, Fournier J‑P et al (2016) Predictors of cardiovascular hospitalization in giant cell arteritis: effect of Statin exposure. A French population-based study. J Rheumatol 43:2162–2170. https://doi.org/10.3899/jrheum.151500

Puppo C, Massollo M, Paparo F et al (2014) Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int 2014:574248. https://doi.org/10.1155/2014/574248

Quartuccio L, Maset M, De Maglio G et al (2012) Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 51:1677–1686. https://doi.org/10.1093/rheumatology/kes127

Quartuccio L, Schiavon F, Zuliani F et al (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu’s arteritis treated with infliximab. Clin Exp Rheumatol 30:922–928

Quinn EM, Kearney DE, Kelly J et al (2012) Temporal artery biopsy is not required in all cases of suspected giant cell arteritis. Ann Vasc Surg 26:649–654. https://doi.org/10.1016/j.avsg.2011.10.009

Quinn KA, Ahlman MA, Malayeri AA et al (2018) Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis 77:1165–1171. https://doi.org/10.1136/annrheumdis-2018-213102

Raine C, Stapleton PP, Merinopoulos D et al (2018) A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis. Int J Rheum Dis 21:285–291. https://doi.org/10.1111/1756-185X.13149

Raninen RO, Kupari MM, Pamilo MS et al (1996) Arterial wall thickness measurements by B mode ultrasonography in patients with Takayasu’s arteritis. Ann Rheum Dis 55:461–465. https://doi.org/10.1136/ard.55.7.461

Restuccia G, Boiardi L, Cavazza A et al (2016) Flares in biopsy-proven giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study. Medicine (Baltimore) 95:e3524. https://doi.org/10.1097/MD.0000000000003524

Restuccia G, Cavazza A, Boiardi L et al (2012) Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis. Arthritis Rheum 64:549–556. https://doi.org/10.1002/art.33362

Riambau V, Böckler D, Brunkwall J et al (2017) Editor’s choice—management of descending thoracic aorta diseases: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 53:4–52. https://doi.org/10.1016/j.ejvs.2016.06.005

Rosa Neto NS, Shinjo SK, Levy-Neto M, Pereira RMR (2017) Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients. Rheumatol Int 37:1065–1073. https://doi.org/10.1007/s00296-017-3656-y

Saadoun D, Lambert M, Mirault T et al (2012) Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 125:813–819. https://doi.org/10.1161/CIRCULATIONAHA.111.058032

Salvarani C, Cimino L, Macchioni P et al (2005) Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53:293–297. https://doi.org/10.1002/art.21075

Salvarani C, Silingardi M, Ghirarduzzi A et al (2002) Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 137:232–238. https://doi.org/10.7326/0003-4819-137-4-200208200-00006

Sammel AM, Hsiao E, Schembri G et al (2019) Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheumatol 71:1319–1328. https://doi.org/10.1002/art.40864

Samson M, Jacquin A, Audia S et al (2015) Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry 86:216–221. https://doi.org/10.1136/jnnp-2014-307614

Sanchez-Alvarez C, Mertz LE, Thomas CS et al (2019) Demographic, clinical, and radiologic characteristics of a cohort of patients with Takayasu arteritis. Am J Med 132:647–651. https://doi.org/10.1016/j.amjmed.2018.12.017

Schäfer VS, Chrysidis S, Dejaco C et al (2018) Assessing vasculitis in giant cell arteritis by ultrasound: results of OMERACT patient-based reliability exercises. J Rheumatol 45:1289–1295. https://doi.org/10.3899/jrheum.171428

Schaufelberger C, Andersson R, Nordborg E (1998) No additive effect of cyclosporin a compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 37:464–465

Schaufelberger C, Möllby H, Uddhammar A et al (2006) No additional steroid-sparing effect of cyclosporine a in giant cell arteritis. Scand J Rheumatol 35:327–329. https://doi.org/10.1080/03009740500474537

Schmidt D, Löffler KU (1994) Temporal arteritis. Comparison of histological and clinical findings. Acta Ophthalmol (Copenh) 72:319–325

Schmidt J, Kermani TA, Bacani AK et al (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res 64:1079–1083. https://doi.org/10.1002/acr.21636

Schmidt J, Smail A, Roche B et al (2016) Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study. Arthritis Rheumatol 68:1477–1482. https://doi.org/10.1002/art.39596

Schmidt WA, Moll A, Seifert A et al (2008) Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 47:1406–1408. https://doi.org/10.1093/rheumatology/ken258

Schmidt WA, Seifert A, Gromnica-Ihle E et al (2008) Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 47:96–101. https://doi.org/10.1093/rheumatology/kem322

Seeliger B, Sznajd J, Robson JC et al (2017) Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (Oxford) 56:1154–1161. https://doi.org/10.1093/rheumatology/kex075

Seko Y, Minota S, Kawasaki A et al (1994) Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu’s arteritis. J Clin Invest 93:750–758. https://doi.org/10.1172/JCI117029

Seror R, Baron G, Hachulla E et al (2014) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 73:2074–2081. https://doi.org/10.1136/annrheumdis-2013-203586

Serra R, Grande R, Buffone G et al (2014) Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J Pharmacol Pharmacother 5:193–196. https://doi.org/10.4103/0976-500X.136101

Shao N, Jia H, Li Y, Li J (2017) Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial. Immunol Res 65:969–974. https://doi.org/10.1007/s12026-017-8917-z

Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141–S147

Sharma BK, Siveski-Iliskovic N, Singal PK (1995) Takayasu arteritis may be underdiagnosed in North America. Can J Cardiol 11:311–316

Sharma S, Sharma S, Taneja K et al (1998) Morphological mural changes in the aorta in non-specific aortoarteritis (Takayasu’s arteritis): assessment by intravascular ultrasound imaging. Clin Radiol 53:37–43

Shi G, Hua M, Xu Q, Ren T (2017) Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: a randomized double-blind and placebo-controlled trial. Immunobiology 222:164–168. https://doi.org/10.1016/j.imbio.2016.10.008

Shinjo SK, Pereira RMR, Tizziani VAP et al (2007) Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 26:1871–1875. https://doi.org/10.1007/s10067-007-0596-z

Slart RHJA et al (2018) FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 45:1250–1269. https://doi.org/10.1007/s00259-018-3973-8

de Souza AWS, de Almeida Agustinelli R, de Cinque Almeida H et al (2016) Leflunomide in Takayasu arteritis—A long term observational study. Rev Bras Reumatol. https://doi.org/10.1016/j.rbr.2015.09.007

de Souza AWS, Machado NP, Pereira VM et al (2010) Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J 74:1236–1241

de Souza AWS, da Silva MD, Machado LSG et al (2012) Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41:227–230. https://doi.org/10.3109/03009742.2011.633553

Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495–501

Stone JH, Bao M, Han J et al (2019) Long-term outcome of Tocilizumab for patients with giant cell arteritis: results from part 2 of the GiACTA trial. Ann Rheum Dis 78(Suppl 2):A145

Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317–328. https://doi.org/10.1056/NEJMoa1613849

Stone JH, Tuckwell K, Dimonaco S et al (2019) Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of Tocilizumab. Arthritis Rheumatol 71:1329–1338. https://doi.org/10.1002/art.40876

Strehl C, Bijlsma JWJ, de Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952–957. https://doi.org/10.1136/annrheumdis-2015-208916

Suematsu R, Tashiro S, Ono N et al (2018) Successful golimumab therapy in four patients with refractory Takayasu’s arteritis. Mod Rheumatol 28:712–715. https://doi.org/10.3109/14397595.2015.1134393

Tengesdal S, Diamantopoulos AP, Myklebust G (2019) Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival. Scand J Rheumatol 48:333–335. https://doi.org/10.1080/03009742.2019.1575980

Terao C, Yoshifuji H, Nakajima T et al (2016) Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol 45:80–82. https://doi.org/10.3109/03009742.2015.1060521

Tombetti E, Franchini S, Papa M et al (2013) Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 40:2047–2051. https://doi.org/10.3899/jrheum.130536

Treitl KM, Maurus S, Sommer NN et al (2017) 3D-black-blood 3T-MRI for the diagnosis of thoracic large vessel vasculitis: a feasibility study. Eur Radiol 27:2119–2128. https://doi.org/10.1007/s00330-016-4525-x

Uddhammar A, Eriksson A‑L, Nyström L et al (2002) Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 29:737–742

Valsakumar AK, Valappil UC, Jorapur V et al (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798

Villiger PM, Adler S, Kuchen S et al (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921–1927. https://doi.org/10.1016/S0140-6736(16)00560-2

Wang X, Dang A, Lv N et al (2017) Long-term outcomes of coronary artery bypass grafting versus percutaneous coronary intervention for Takayasu arteritis patients with coronary artery involvement. Semin Arthritis Rheum 47:247–252. https://doi.org/10.1016/j.semarthrit.2017.03.009

Warrington KJ, Weyand CM (2014) Giant cell arteritis and polymyalgia rheumatica. In: Ball GV, Fessler BJ, Bridges SL (Hrsg) Oxf. Textb. Vasc., 3. Aufl. Oxford University Press, Oxford, S 307–318

Watts R, Al-Taiar A, Mooney J et al (2009) The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 48:1008–1011. https://doi.org/10.1093/rheumatology/kep153

Weaver FA, Kumar SR, Yellin AE et al (2004) Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg 39:749–757. https://doi.org/10.1016/j.jvs.2003.12.022

Weiner SM, Bergner R (2015) Dosage and toxicity of antirheumatic drugs in renal insufficiency. Z Rheumatol 74:300–309. https://doi.org/10.1007/s00393-014-1480-2

Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349:160–169. https://doi.org/10.1056/NEJMra022694

Wilson JC, Sarsour K, Collinson N et al (2017) Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum 46:819–827. https://doi.org/10.1016/j.semarthrit.2016.11.006

Wilson JC, Sarsour K, Collinson N et al (2017) Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis. Semin Arthritis Rheum 46:650–656. https://doi.org/10.1016/j.semarthrit.2016.10.001

Xiao Y, Zhou J, Wei X et al (2016) Outcomes of different treatments on Takayasu’s arteritis. J Thorac Dis 8:2495–2503. https://doi.org/10.21037/jtd.2016.08.12

Yachoui R, Kreidy M, Siorek M, Sehgal R (2018) Successful treatment with ustekinumab for corticosteroid- and immunosuppressant-resistant Takayasu’s arteritis. Scand J Rheumatol 47:246–247. https://doi.org/10.1080/03009742.2017.1278788

Yamada I, Nakagawa T, Himeno Y et al (2000) Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging 11:481–487

Yang Y, Tian T, Yang K et al (2017) Outcomes of percutaneous coronary intervention and coronary artery bypass grafting in patients with Takayasu arteritis. Int J Cardiol 241:64–69. https://doi.org/10.1016/j.ijcard.2017.02.041

Yates M, MacGregor AJ, Robson J et al (2017) The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology (Oxford) 56:524–528. https://doi.org/10.1093/rheumatology/kew397

Yilmaz N, Can M, Oner FA et al (2013) Impaired quality of life, disability and mental health in Takayasu’s arteritis. Rheumatology (Oxford) 52:1898–1904. https://doi.org/10.1093/rheumatology/ket238

Ypsilantis E, Courtney ED, Chopra N et al (2011) Importance of specimen length during temporal artery biopsy. Br J Surg 98:1556–1560. https://doi.org/10.1002/bjs.7595

Zhou J, Chen Z, Li J et al (2017) The efficacy of tocilizumab for the treatment of Chinese Takayasu’s arteritis. Clin Exp Rheumatol 35(Suppl 103):171–175